Pathology in Sweden: Diarrhea - Pipeline Review, H2 2011

• Publication date: October 2011

This report provides information on the therapeutic development for Diarrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diarrhea. '' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases fr...

This report provides information on the therapeutic development for Diarrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diarrhea. '' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of the Research

- A snapshot of the global therapeutic scenario for Diarrhea.
- A review of the Diarrhea products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diarrhea pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Identify and understand important and diverse types of therapeutics under development for Diarrhea.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Diarrhea therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Global Pathology Industry

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global March kets Direct Report Coverage 7
Diarrhea Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Diarrhea 9
Diarrhea Therapeutics under Development by Firms 11
Diarrhea Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Pre-Clinical Stage Products 18
Comparative Analysis 18
Diarrhea Therapeutics - Products under Development by Firms 19
Diarrhea Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Diarrhea Therapeutics Development 22
Ipsen S.A. 22
Astellas Pharma Inc. 22
Menarini Group 23
Shire Plc 23
Cosmo Pharmaceuticals S.p.A 24
Pharmos Corporation 24
AGI Therapeutics plc 25
Creative Antibiotics Sweden AB 25
Helsinn Healthcare S.A. 26
Osel Inc. 26
Tranzyme Pharma, Inc. 27
Rottapharm SpA 27
Tioga Pharmaceuticals, Inc. 28
Napo Pharmaceuticals, Inc. 28
Dr. Falk Pharma GmbH 29
Kemin Market, Inc. 29
Diarrhea - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
Irribow - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Ibodutant - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Crofelemer - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
TZP-201 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Asimadoline - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Rifamycin SV MMX - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ACAM-CDIFF - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Dextofisopam - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ZP1846 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
AGI-004 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Anaeban - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Inflammaban - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Mesalazine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Somatuline - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Glutamine + Irinotecan + Fluorouracil - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Rifaximin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
WRSS1 Vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Saccharomyces Boulardii - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Mu Delta - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Culturelle - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MIYA-BM - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CR-3294 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
April iso - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
INP-1855 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Library 1 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Diarrhea Therapeutics – Drug Profile Updates 62
Diarrhea Therapeutics - Discontinued Products 65
Diarrhea - Featured News 66
September 29, 2011: Cubist Pharmaceuticals To Move CDAD Candidate CB-183,315 Into Phase III Trial For Treatment Of Diarrhea 66
September 23, 2011: Optimer And Astellas Receive Positive Opinion From CHMP For European Approval Of DIFICID 66
September 06, 2011: Furiex Reports Positive Phase II Results For MuDelta In Diarrhea-Predominant Irritable Bowel Syndrome 66
May 27, 2011: Optimer Receives FDA Approval For DIFICID Tablets For Treatment Of Patients With CDAD 68
April 20, 2011: Salix Pharmaceuticals Secures Additional Intellectual Property Relating To Rifaximin 69
February 14, 2011: Napo Pharmaceuticals Announces Positive Results From Phase II study of Crofelemer 70
February 07, 2011: Glenmark Announces Positive Results From Multi-Center Study Of Crofelemer In Adult Acute Diarrhoea 70
January 24, 2011: Furiex Receives FDA Fast Track Designation Of MuDelta For Treatment Of Diarrhea-Predominant Irritable Bowel Syndrome 71
November 04, 2010: Salix's Crofelemer Advent Trial Demonstrates Statistically Significant Results In Treatment Of HIV-Associated Diarrhea 72
October 20, 2008: Data From Optimer Pharmaceuticals Prulifloxacin Phase III Trial In Travelers Diarrhea And Strain Typing Data From OPT-80 Study To Be Presented At ICAAC/IDSA Annual Meeting 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 75
Contact Us 75
Disclaimer 75

List of Tables

Number of Products Under Development for Diarrhea, H2 2011 9
Products under Development for Diarrhea – Comparative Analysis, H2 2011 10
Number of Products under Development by Firms, H2 2011 12
Number of Products under Investigation by Universities/Institutes, H2 2011 14
Comparative Analysis by Late Stage Development, H2 2011 15
Comparative Analysis by Mid Clinical Stage Development, H2 2011 16
Comparative Analysis by Early Clinical Stage Development, H2 2011 17
Comparative Analysis by Pre-Clinical Stage Development, H2 2011 18
Products under Development by Firms, H2 2011 19
Products under Development by Firms, H2 2011 20
Products under Investigation by Universities/Institutes, H2 2011 21
Ipsen S.A., H2 2011 22
Astellas Pharma Inc., H2 2011 22
Menarini Group, H2 2011 23
Shire Plc, H2 2011 23
Cosmo Pharmaceuticals S.p.A, H2 2011 24
Pharmos Corporation, H2 2011 24
AGI Therapeutics plc, H2 2011 25
Creative Antibiotics Sweden AB, H2 2011 25
Helsinn Healthcare S.A., H2 2011 26
Osel Inc., H2 2011 26
Tranzyme Pharma, Inc., H2 2011 27
Rottapharm SpA, H2 2011 27
Tioga Pharmaceuticals, Inc., H2 2011 28
Napo Pharmaceuticals, Inc., H2 2011 28
Dr. Falk Pharma GmbH, H2 2011 29
Kemin Market, Inc., H2 2011 29
Assessment by Monotherapy Products, H2 2011 30
Assessment by Combination Products 31
Assessment by Stage and Route of Administration, H2 2011 33
Assessment by Molecule Type, H2 2011 35
Diarrhea Therapeutics – Drug Profile Updates 62
Discontinued Products 65

List of Figures

Number of Products under Development for Diarrhea, H2 2011 9
Products under Development for Diarrhea – Comparative Analysis, H2 2011 10
Products under Development by Firms, H2 2011 11
Products under Investigation by Universities/Institutes, H2 2011 13
Late Stage Products, H2 2011 15
Mid Clinical Stage Products, H2 2011 16
Early Clinical Stage Products, H2 2011 17
Pre-Clinical Stage Products, H2 2011 18
Assessment by Monotherapy Products, H2 2011 30
Assessment by Combination Products, H2 2011 31
Assessment by Route of Administration, H2 2011 32
Assessment by Stage and Route of Administration, H2 2011 33
Assessment by Molecule Type, H2 2011 34
Assessment by Stage and Molecule Type, H2 2011 35